Delivery Technologies for Protein Therapeutics: Assessment and Outlook
Tom Hollon, PhD
Some of biotech’s most celebrated successes include:
- clotting factors
- modern insulins
- growth hormone
- follicle-stimulating hormone
- hematopoietic growth factors
What do they have in common?
They are therapeutic proteins, a market segment that had $34 billion in sales in 2004 and will have a projected $52.2 billion in sales in 2010*. As patents on first-generation proteins wind down, their owners naturally seek to protect their markets against interlopers. And in current and future battles for market share, protein delivery technologies are major weapons of offense and defense. It is a safe bet that if a therapeutic protein is bringing in big money and its patent is nearing expiration, someone somewhere with a clever technology is planning a market invasion based on improving how the protein is delivered.
Delivery Technologies for Therapeutic Proteins: Assessment and Outlook analyzes and assesses protein delivery technologies developed by companies that are targeting:
- improved insulin delivery
- improved erythropoietin delivery
- improved interferon delivery
- improved growth hormone delivery
The report also analyzes and assesses noninjection delivery technologies, including technologies for:
- transdermal protein delivery
- oral protein delivery
- pulmonary protein delivery
- nasal protein delivery
Delivery Technologies for Therapeutic Proteins: Assessment and Outlook provides a thorough analysis and assessment of technologies for protein half-life extension and technologies for delivery of protein therapeutics.
SWOT: Strengths, Weaknesses, Opportunities, and Threats: SWOT charts are rich and easy-to-scan snapshots of the commercial viability of a complex technology. Delivery Technologies for Therapeutic Proteins: Assessment and Outlook includes 22 SWOT charts evaluating the pros and cons of delivery technologies for therapeutic proteins.
The Views, Practices, and Plans of Your Peers Working in Protein Delivery R&D
You also get the results of a quantitative survey of individuals working in various aspects of protein delivery R&D - results that point to injection delivery continuing to be the major delivery method, and PEGylation continuing to be the dominant half-life extension technology in the near term, but results that also show that more delivery methods (e.g., Exubera) and half-life extension technologies (e.g., Protease Resistance Technology) are gaining ground.
Technologies discussed in this report are those most likely to affect the delivery of therapeutic proteins within the next 5 years. They are being tested today in clinical trials, or will be within a few years. They are not embryonic technologies under development in academic laboratories.
Delivery Technologies for Therapeutic Proteins: Assessment and Outlook is an indispensable report for individuals involved in the research, development, or commercialization of therapeutic proteins.
About the Author
Tom Hollon, PhD, president of Falcon River Biocommunications (www.falconriver.com), is a science writer and consultant who has provided professional services to more than 40 biotech companies, foundations, universities, and science publications. Author of more than 100 articles on subjects ranging from oncology, to drug discovery and clinical trials, to genomics, he was also the founding editor of Modern Drug Discovery magazine in the late 1990s. Earlier, he was a senior staff fellow in the Laboratory of Molecular Neuropharmacology at the National Institutes of Health. He earned his PhD in microbiology at the University of Washington, Seattle, and served as a postdoctoral fellow in the Mouse Embryology Unit at the Pasteur Institute, Paris. Dr. Hollon is based in Rockville, MD, and can be reached at 301-468-9510 or email@example.com.
* Pavlou AK and Reichert JM. Recombinant Protein Therapeutics—Success Rates, Market Trends and Values to 2010. Nat Biotech. 2004;22:1513-1519.